AST SpaceMobile Wins U.S. Space Force Contract
AST SpaceMobile will support prime contractor STR under a new U.S. Space Force contract to develop its space-based cellular broadband network.
Stocks · News reference
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed; First Tracks Biotherapeutics surged 18% on positive celiac trial results, while C3.ai, Liquidia and others also gained.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Computacenter plc Director/PDMR Shareholding Notification
Computacenter plc announced the grant of share options to a Director under the company's 2026 Sharesave Scheme.
AST SpaceMobile Stock Slides Thursday Despite Space Force Contract: What’s Going On?
Shares of AST SpaceMobile Inc (NASDAQ:ASTS) are moving lower on Thursday, even after the company was awarded a U.S. Space Force contract. Here’s what you need to know.
Allot Ltd. Highlights New Capabilities for Securing SIM-Enabled IoT Devices
Allot Ltd. has introduced new capabilities for its NetworkSecure platform designed to protect SIM-enabled IoT devices on 4G and 5G networks from cyber threats.
AST SpaceMobile Secures U.S. Space Force Contract Support Role To Advance Commercial Space-Based Sensing Technology
Should You Buy C3.ai Stock After Its 93% Decline? The Answer Might Surprise You.
C3.ai stock has plummeted 93% from its all-time high of $177 following founder Thomas Siebel's temporary departure last year, which disrupted sales and customer relationships. After Siebel's return in May, the company is attempting a turnaround by shifting to an AI platform provider strategy. While gross bookings surged 73% quarter-over-quarter suggesting potential revenue recovery, the analyst recommends waiting for consistent revenue growth before investing, as the company's forward valuation remains expensive relative to its shrinking revenues.